Bir sonraki

Otomatik oynatma

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

2 Görünümler • 07/14/23
Pay
gömmek
administrator
administrator
Aboneler
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Daha fazla göster
0 Yorumlar sort Göre sırala
Facebook Yorumları

Bir sonraki

Otomatik oynatma